Deutsche Bank AG Boosts Holdings in iTeos Therapeutics, Inc. $ITOS

Deutsche Bank AG grew its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 168.0% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 33,586 shares of the company’s stock after buying an additional 21,055 shares during the quarter. Deutsche Bank AG owned 0.09% of iTeos Therapeutics worth $201,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of ITOS. Charles Schwab Investment Management Inc. grew its position in shares of iTeos Therapeutics by 17.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 233,561 shares of the company’s stock worth $1,394,000 after buying an additional 34,365 shares during the last quarter. CWM LLC lifted its holdings in iTeos Therapeutics by 428.7% in the first quarter. CWM LLC now owns 8,554 shares of the company’s stock valued at $51,000 after acquiring an additional 6,936 shares during the period. Peapod Lane Capital LLC raised its position in shares of iTeos Therapeutics by 24.6% in the first quarter. Peapod Lane Capital LLC now owns 135,655 shares of the company’s stock worth $810,000 after acquiring an additional 26,802 shares during the period. Exchange Traded Concepts LLC increased its position in shares of iTeos Therapeutics by 25.1% in the first quarter. Exchange Traded Concepts LLC now owns 17,308 shares of the company’s stock valued at $103,000 after buying an additional 3,468 shares in the last quarter. Finally, Wellington Management Group LLP lifted its position in shares of iTeos Therapeutics by 4.3% in the fourth quarter. Wellington Management Group LLP now owns 110,332 shares of the company’s stock valued at $847,000 after acquiring an additional 4,563 shares in the last quarter. 97.16% of the stock is owned by institutional investors.

iTeos Therapeutics Price Performance

Shares of NASDAQ ITOS opened at $10.15 on Friday. The stock has a market capitalization of $448.73 million, a P/E ratio of -2.17 and a beta of 1.49. The firm’s 50-day moving average price is $10.14 and its two-hundred day moving average price is $8.44. iTeos Therapeutics, Inc. has a 52-week low of $4.80 and a 52-week high of $17.63.

iTeos Therapeutics (NASDAQ:ITOS) last posted its earnings results on Wednesday, August 6th. The company reported ($1.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.39). As a group, equities research analysts expect that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

Insider Buying and Selling at iTeos Therapeutics

In other news, CEO Michel Detheux sold 43,883 shares of the business’s stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $10.02, for a total value of $439,707.66. Following the sale, the chief executive officer owned 153,903 shares of the company’s stock, valued at approximately $1,542,108.06. The trade was a 22.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David Hallal sold 38,228 shares of iTeos Therapeutics stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $10.24, for a total transaction of $391,454.72. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 277,185 shares of company stock worth $2,805,412. 14.20% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms have commented on ITOS. JPMorgan Chase & Co. cut shares of iTeos Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $15.00 to $8.00 in a research report on Tuesday, May 13th. Wells Fargo & Company cut their target price on iTeos Therapeutics from $12.00 to $11.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 7th. Wedbush reissued an “outperform” rating and issued a $10.50 target price (down previously from $12.00) on shares of iTeos Therapeutics in a report on Monday, July 21st. Wall Street Zen raised shares of iTeos Therapeutics to a “sell” rating in a research note on Saturday. Finally, Leerink Partners reiterated a “market perform” rating and set a $9.00 target price (down previously from $47.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. One analyst has rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $15.50.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.